BOTHELL, Wash. and VANCOUVER, British Columbia, July 21, 2016 /PRNewswire/ -- OncoGenexPharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its second quarter 2016 financial results on Thursday, August 4, 2016. Company management will host a conference call and live webcast at 4:30
To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.
ABOUT ONCOGENEXOncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account: https://twitter.com/OncoGenex_IR.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncogenex-to-report-second-quarter-2016-financial-results-on-august-4-2016-300301566.html
SOURCE OncoGenex Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...
Strabismus or squint is a failure of the two eyes to maintain proper alignment when looking at an ...View All